Skip to content
Bharat Biotech Expects Nasal Covid-19 Vaccine Approval This Month – Some Benefits This Vaccine Can Offer

Hyderabad-based vaccine maker Bharat Biotech is awaiting regulatory licenses for its intranasal COVID-19 vaccine candidate BBV-154 in August.

Krishna Ella, Chairman and Managing Director of the company, said: “We will apply for licenses… If all goes well, we will know by next month (August). You (people) would rather get the vaccine nasal against coronavirus….we are optimistic that the injectable and nasal strategy will work to protect people’s lives in the future.”

Benefits of the COVID-19 Nasal Vaccine

Talking about the benefits of the nasal injection, Ella was quoted by news agency PTI as saying that any injectable vaccine only protects the lower level (of the body). This is why people who have been vaccinated with injectable vaccines can still be RT-PCR positive, whereas the nasal prick protects the whole body.

The company has completed clinical trials of the nasal vaccine with about 4,000 volunteers, Ella said. He mentioned that no case of any side effect or adverse reaction has been reported so far. Bharat Biotech also claims that the “intranasal vaccine stimulates a broad immune response”

Other benefits: As mentioned by Bharat Biotech, the nasal vaccine is:

  • Likely to block both infection and transmission of COVID-19
  • Non-invasive and needle-free
  • Easy to administer as it does not require trained health personnel
  • Eliminates the risks associated with needles (injuries and infections)
  • High compliance – perfectly suitable for children and adults
  • Scalable manufacturing — able to meet global demand
  • (Credit:

    “COVID hospitalizations will increase”

    In response to a question, Ella predicted that the country could face higher hospitalizations with the emerging variant of the BA.5 coronavirus, as the new form may evade the vaccine.

    “It’s totally different from the Delta variant. It’s also totally different from omicron. They call it ‘deltamicron’, a combination of the two. I think if it attacks it’s going to be a problem. But we continue to monitor “We’re working on that too. Risk mitigation we’re trying to do. We’re well prepared now…I think hospitalizations will increase if there are BA.5 attacks,” Ella said.

    On the monkeypox vaccine

    Following emerging cases of monkeypox in India, Ella said BBIL’s Gujarat factory is one of two factories in the world capable of producing a monkeypox disease vaccine. The other is in northern Bavaria, Germany.

    (Inputs from PTI)

    (Edited by : Akriti Anand)


    Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.